Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

102.69
+1.631.61%
Post-market: 102.690.00000.00%19:30 EDT
Volume:458.31K
Turnover:46.77M
Market Cap:4.67B
PE:50.09
High:102.89
Open:101.70
Low:100.53
Close:101.06
52wk High:109.57
52wk Low:47.32
Shares:45.45M
Float Shares:44.60M
Volume Ratio:0.81
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.05
EPS(LYR):2.05
ROE:11.20%
ROA:6.60%
PB:5.58
PE(LYR):50.09

Loading ...

How Investors Are Reacting To BioCryst (BCRX) Expanding Its HAE Prophylaxis Data Across Patient Groups

Simply Wall St.
·
Jun 15

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

GlobeNewswire
·
Jun 12

Is Haemonetics’ (HAE) Apheresis Reorg Quietly Redefining Its Competitive Edge in Medical Devices?

Simply Wall St.
·
Jun 11

Pharvaris Announces Annual General Meeting of Shareholders

GlobeNewswire
·
Jun 11

Haemonetics announces annual shareholder meeting

Reuters
·
Jun 10

A Look At Intellia Therapeutics (NTLA) Valuation After Phase 3 HAE Success And Equity Raise

Simply Wall St.
·
Jun 10

Haemonetics: Buy Rating Reiterated as New Apheresis Reporting Boosts Transparency; $80 Price Target Maintained

TIPRANKS
·
Jun 08

Sector Update: Healthcare Stocks Higher Late Afternoon

MT Newswires Live
·
Jun 06

Haemonetics Narrows Reporting Structure

MT Newswires Live
·
Jun 05

Haemonetics combines Plasma and Blood Center units into new Apheresis reporting segment

Reuters
·
Jun 05

Haemonetics Updates Financial Reporting Segments

THOMSON REUTERS
·
Jun 05

Haemonetics - to Report Under New Segment Structure Beginning Q1 FY2027

THOMSON REUTERS
·
Jun 05

Haemonetics CEO Simon to speak at Goldman Sachs Global Healthcare Conference

Reuters
·
Jun 03

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

GlobeNewswire
·
Jun 01

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

GlobeNewswire
·
May 29

Haemonetics Is Maintained at Neutral by Citigroup

Dow Jones
·
May 29

New Data Highlights Heavy Burden of Injectable Treatments for Young HAE Patients

Deep News
·
May 28

Haemonetics price target raised to $70 from $64 at Citi

TIPRANKS
·
May 28

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

GlobeNewswire
·
May 27

Haemonetics Likely to See Upside as Core Businesses Improve, BofA Securities Says

MT Newswires Live
·
May 22